Profile data is unavailable for this security.
About the company
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
- Revenue in EUR (TTM)102.00k
- Net income in EUR-8.45m
- Incorporated2007
- Employees12.00
- LocationCelyad Oncology SARue Andre Dumont 9MONT-SAINT-GUIBERT 1435BelgiumBEL
- Phone+32 10394100
- Fax+32 10394141
- Websitehttps://www.celyad.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genflow Biosciences PLC | 0.00 | -1.94m | 8.32m | 5.00 | -- | 8.06 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -88.30 | -- | -105.34 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
Acticor Biotech SA | 0.00 | -18.64m | 8.67m | 28.00 | -- | -- | -- | -- | -1.55 | -1.55 | 0.00 | -0.4028 | 0.00 | -- | -- | 0.00 | -164.53 | -- | -568.29 | -- | -- | -- | -- | -- | -- | -19.85 | 10.47 | -- | -- | -- | -17.40 | -- | -- | -- |
GENOMED SA | 5.08m | 106.66k | 8.77m | 44.00 | 82.27 | 3.97 | 36.08 | 1.73 | 0.3452 | 0.3452 | 16.45 | 7.15 | 2.06 | 5.94 | 11.85 | 493,900.20 | 4.33 | 7.77 | 4.82 | 9.19 | 42.78 | 38.53 | 2.10 | 3.87 | 5.00 | 1,435.88 | 0.00 | -- | 9.88 | 3.88 | 174.07 | -8.94 | -32.19 | -- |
Medicofarma Biotech SA | 317.71k | -672.45k | 8.90m | -- | -- | 3.84 | -- | 28.02 | -0.0423 | -0.0423 | 0.02 | 0.1459 | 0.0866 | 5.56 | 2.83 | -- | -18.34 | -15.05 | -23.49 | -18.17 | 78.54 | 29.92 | -211.65 | -42.86 | 0.805 | -16.98 | 0.00 | -- | -82.34 | -31.48 | -116.39 | -- | -- | -- |
AroCell AB (publ) | 3.83m | -4.80m | 9.07m | -- | -- | 0.6919 | -- | 2.37 | -0.2437 | -0.2437 | 0.1944 | 0.6648 | 0.2325 | 5.82 | 5.63 | -- | -29.14 | -29.25 | -31.00 | -31.37 | 1.88 | -9.85 | -125.33 | -231.19 | 5.16 | -- | 0.00 | -- | 16.37 | 122.92 | -0.5494 | -- | -- | -- |
ImmuPharma PLC | 0.00 | -3.47m | 9.17m | 5.00 | -- | 7.30 | -- | -- | -0.0081 | -0.0081 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -87.27 | -86.13 | -163.24 | -106.39 | -- | -- | -- | -8,634.98 | -- | -8.61 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
Cizzle Biotechnology Holdings PLC | 0.00 | -2.04m | 9.90m | 67.00 | -- | 5.07 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
NextCell Pharma AB | 1.07m | -3.37m | 10.32m | -- | -- | 1.29 | -- | 9.69 | -0.9046 | -0.9046 | 0.286 | 1.28 | 0.1406 | 14.06 | 7.20 | -- | -44.45 | -34.92 | -50.09 | -37.06 | 12.04 | -68.21 | -316.25 | -538.60 | 4.36 | -- | 0.00 | -- | 80.96 | 72.85 | -15.21 | -- | -- | -- |
Celyad Oncology SA | 102.00k | -8.45m | 10.56m | 12.00 | -- | 1.68 | -- | 103.57 | -0.3287 | -0.3287 | 0.004 | 0.1522 | 0.0057 | -- | 0.1583 | 8,500.00 | -46.94 | -39.16 | -74.63 | -47.45 | 32.35 | 38.94 | -8,282.35 | -107,726.50 | -- | -156.61 | 0.1437 | -- | -- | -49.53 | 79.36 | -- | -11.95 | -- |
Spago Nanomedical AB (publ) | 125.45k | -3.04m | 11.32m | 12.00 | -- | 2.49 | -- | 90.26 | -0.3129 | -0.3129 | 0.0113 | 0.1525 | 0.0324 | -- | 9.91 | 112,769.20 | -78.60 | -20.19 | -93.27 | -20.97 | -5.25 | -- | -2,426.88 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
Synairgen plc | 0.00 | -10.00m | 11.39m | 36.00 | -- | 0.7565 | -- | -- | -0.0418 | -0.0418 | 0.00 | 0.0629 | 0.00 | -- | -- | 0.00 | -44.55 | -54.01 | -51.06 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
Addex Therapeutics Ltd | 1.43m | -9.19m | 12.16m | 23.00 | -- | -- | -- | 8.52 | -0.1116 | -0.1357 | 0.0166 | -0.014 | 0.2596 | -- | 8.91 | 59,997.39 | -167.14 | -69.05 | -637.08 | -84.19 | -- | -- | -643.81 | -572.59 | -- | -36.25 | -- | -- | 13.99 | -24.47 | 49.26 | -- | -5.45 | -- |
Coegin Pharma AB | 0.00 | -2.39m | 12.22m | 0.00 | -- | 10.96 | -- | -- | -2.65 | -2.65 | 0.00 | 0.6403 | 0.00 | -- | -- | -- | -125.24 | -122.02 | -201.53 | -154.70 | -- | -- | -- | -28,466.75 | -- | -170.65 | 0.00 | -- | -- | -- | 20.60 | -- | -- | -- |
Wntresearch AB | 0.00 | -3.07m | 12.23m | 2.00 | -- | 3.51 | -- | -- | -9.19 | -9.19 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -89.47 | -100.71 | -103.70 | -123.59 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.65 | -- | -- | -- |
Bivictrix Therapeutics PLC | 0.00 | -3.03m | 12.76m | 12.00 | -- | 3.03 | -- | -- | -0.0351 | -0.0351 | 0.00 | 0.0429 | 0.00 | -- | -- | 0.00 | -57.64 | -- | -65.12 | -- | -- | -- | -- | -- | -- | -- | 0.069 | -- | -- | -- | -1.92 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BNP Paribas Asset Management Belgium SAas of 30 Jun 2024 | 72.64k | 0.18% |
Gestys SAas of 26 Jan 2024 | 28.00k | 0.07% |
Iris Finance SAas of 31 Dec 2018 | 0.00 | 0.00% |